What Biragan Codein (Acetaminophen, Codeine) Treats: Main Uses and Benefits

The combination of acetaminophen and codeine is commonly used to help with symptoms related to moderate to severe physical discomfort. The combination is commonly used when short-term symptomatic assistance is needed, providing support when symptoms are not adequately addressed by non-opioid medications alone.

This approach is often relevant for managing conditions associated with acute or disruptive episodes, scenarios where additional management of discomfort is required after procedures, situations involving physical trauma, and symptoms related to systemic imbalance, such as fever, when they appear together. The medication may assist with managing symptoms that create noticeable functional strain and is relevant for easing symptoms that interfere with daily comfort. It supports patients during episodes of heightened discomfort, helping them cope more steadily with symptom fluctuations.

---

Quick Fact: Relief for Moderate to Severe Discomfort

Who can and cannot use Biragan Codein (Acetaminophen,Codeine)?

The eligibility for this medication is defined by regulatory authorities based on specific age, metabolic, and health status constraints, primarily due to the codeine component.

Absolute Contraindications

Use is contraindicated in several populations to prevent life-threatening risks:

• Children younger than 12 years of age for all uses.
• Pediatric patients younger than 18 years of age following tonsillectomy and/or adenoidectomy.
• Women during breastfeeding.
• Patients known to be CYP2D6 ultra-rapid metabolizers.
• Patients with significant respiratory depression, acute/severe bronchial asthma, or gastrointestinal obstruction (e.g., paralytic ileus).
• Patients currently taking or who have recently taken Monoamine Oxidase Inhibitors (MAOIs).

Restricted or Conditional Use

Certain populations require caution and monitoring, and may be restricted based on individual patient assessment:

• Patients with severe renal impairment or severe hepatic insufficiency.
• Adolescents aged 12 to 18 with risk factors for breathing problems (use is generally avoided).
• Pregnant women are not recommended to use the medication for prolonged periods due to the risk of Neonatal Opioid Withdrawal Syndrome (NOWS).
• Elderly patients and those with conditions such as increased intracranial pressure or seizure disorders are subject to special regulatory caution.

Interactions with Other Medicines and Products

Official regulatory information emphasizes several clinically significant interaction domains for the combination of Acetaminophen and Codeine.

Formally Contraindicated Combinations

• Monoamine Oxidase Inhibitors (MAOIs): Co-administration with MAOIs, or use within 14 days of stopping an MAOI (e.g., Isocarboxazid, Phenelzine), is officially contraindicated due to the risk of severe reactions, including Serotonin Syndrome.
• Opioid Antagonists: Use with certain opioid antagonists or mixed agonist/antagonist analgesics (e.g., Samidorphan) is restricted as they may reduce the pain-relieving effects or precipitate withdrawal symptoms.

Pharmacodynamic & Exposure Interactions

The most serious interaction warnings relate to the combined depressant effects on the central nervous system (CNS):

Interacting Substance/Class	Official Interaction Description
CNS Depressants & Alcohol	Additive CNS depression may lead to profound sedation, respiratory depression, coma, and death. Alcohol must be strictly avoided.
Serotonergic Drugs	May increase the risk of Serotonin Syndrome when taken with medicines like certain antidepressants (SSRIs, SNRIs).
Other Acetaminophen Products	Co-administration increases the total exposure to acetaminophen, raising the documented risk of hepatotoxicity (liver damage).
Warfarin	Prolonged use of the acetaminophen component may potentiate the effects of coumarin anticoagulants like Warfarin, increasing the risk of bleeding.

Metabolic Pathway Interference

The effects of Codeine are dependent on its conversion by specific liver enzymes. The regulatory profile notes that inhibitors of CYP2D6 (e.g., Bupropion, Quinidine) may decrease the formation of the active metabolite, potentially reducing effectiveness. Conversely, CYP3A4 inhibitors (e.g., Ketoconazole) may increase Codeine concentrations, while CYP3A4 inducers (e.g., Rifampin) may cause opposite effects, requiring caution.

How Biragan Codein Works

Opioid Receptor Agonism: Interrupting Pain Signals

The Codeine component is metabolized into morphine, which functions as an agonist at mu-opioid receptors (mu-OR) throughout the central nervous system, including the spinal cord and brain. Activating these inhibitory G-protein coupled receptors triggers a hyperpolarization of neurons and inhibits the presynaptic release of excitatory neurotransmitters. This process effectively dampens the transmission of ascending nociceptive (pain) signals and limits the information transmitted to the higher brain centers for processing.

Central Enzyme Inhibition: Modulating Mediators

The Acetaminophen component acts by inhibiting specific cyclooxygenase (COX) enzyme isoforms primarily within the central nervous system. This molecular interaction reduces the synthesis of prostaglandins, which are key neuromodulators involved in initiating a high body temperature set-point and centrally sensitizing nerves to input. The subsequent reduction of these mediators helps reset the hypothalamic temperature set point and supports the regulation of central pain processes through distinct pathways. The combination engages multiple regulatory systems involved in nociception.

Administration Guidelines

The following outlines the instructions for using the combination of acetaminophen and codeine, focusing on the procedural, dose, and frequency rules.

Property	Standardized Instruction
Route of Administration	The medication is indicated for the oral route only, available as tablets, capsules, or oral solutions.
Dosing Schedule & Limits	Dosing is individualized, but the adult dose of the codeine component typically ranges from 15 mg to 60 mg per administration. The total daily intake of acetaminophen from all sources must not exceed 4,000 mg (4 grams).
Frequency & Timing	Doses are administered as needed for pain, with a minimum required interval of 4 hours between administrations.
Preparation Requirements	For the oral solution, doses must be measured using a marked measuring cup or syringe, not a household spoon, to ensure accuracy.
Course Duration	Use is constrained to a short duration; treatment is often limited to 3 days for acute pain.
Age-Group Rules	The medication is contraindicated in all children younger than 12 years of age. It is also contraindicated in children under 18 following tonsillectomy and/or adenoidectomy.

These instructions define the standardized, constrained conditions under which the product is intended for use, establishing the limits on dosage amount, frequency, duration, and patient eligibility.

Recent Clinical Evidence

Summary of Clinical Studies

Research has explored whether the combination of acetaminophen and codeine could be used for managing moderate to severe pain that has not responded adequately to standard treatments. Studies also investigated outcomes related to pain intensity reduction and evaluated effects on quality of life. The research utilized randomized controlled trials (RCTs) typically lasting between 4 and 12 weeks.

Efficacy Data

• Pain Intensity Scales: Trial outcomes included reported changes on numerical rating scales (NRS) for pain. In one Phase 3 trial, a mean change from baseline on the 11-point NRS was reported over a 12-week period. This result was compared against a placebo group.
• Need for Rescue Medication: One outcome observed in trials was a reduction in the need for rescue medication. Research compared this regimen to standard single-drug therapy.

Safety and Tolerability Profiles

Safety profiles were investigated in adult patients. The studies noted common adverse events consistent with opioid and non-opioid analgesic classes, including nausea, dizziness, and constipation.

Patients with pre-existing kidney or liver problems were generally excluded from the studies, as the medicine's components rely on these organs for metabolism and clearance. This population was not the focus of the included research.

Dosing Regimens Used in Research

The studies utilized the target dose range, which was individually adjusted during an initial titration phase based on patient need. The maximum doses examined were consistent with established limits for the individual components. The final maintenance doses evaluated in the studies had a frequency of twice daily.

Key Studies & References NICE Guideline NG104: Chronic primary pain in over 16s: assessment of all chronic primary pain and management of chronic primary pain of any type

Common questions about Biragan Codein (Acetaminophen,Codeine) (FAQ)

Q: What is the primary medical use of Biragan Codein?

A: According to official product information, Biragan Codein is primarily indicated for the relief of mild to moderately severe pain. This product combines an opioid pain reliever (codeine) with a non-opioid pain reliever (acetaminophen). The codeine component works by altering the way the brain and nervous system process pain signals, while acetaminophen also contributes to pain and fever reduction.

Q: Is Biragan Codein a narcotic or opioid medication?

A: Yes, regulatory documents indicate that Biragan Codein contains codeine, which is classified as an opiate or narcotic analgesic. Opioid-containing medicines are prescribed for pain relief. Regulatory documents state that use should be strictly followed as prescribed by a healthcare professional due to the potential for abuse and physical dependence.

Q: What is the maximum daily dose of acetaminophen I can take in Biragan Codein?

A: Official guidelines emphasize that the total daily intake of acetaminophen from all sources, including Biragan Codein, should not exceed the regulatory maximum limit, typically 4,000 mg (4 grams) for adults. Exceeding this limit, even unintentionally, may result in severe and potentially irreversible liver damage. Patients are advised to monitor the total acetaminophen content across all medications being used.

Q: Are there any age restrictions for using Biragan Codein?

A: Official safety communications state that codeine-containing products, including Biragan Codein, should not be used in children younger than 12 years of age. This restriction is based on the risk of serious breathing problems. Use in adolescents aged 12 to 18 is also typically restricted if certain risk factors, such as obstructive sleep apnea or severe lung conditions, are present.

Q: Can I use this medication while pregnant or breastfeeding?

A: Official warnings advise against using codeine-containing products during breastfeeding. The medication is known to pass into breast milk, which can cause serious adverse effects in a nursing infant, such as difficulty breathing or excessive drowsiness. During pregnancy, the decision to use this combination requires careful consideration based on medical guidance.

Q: Can I take Biragan Codein if I have a history of liver or kidney problems?

A: Regulatory information indicates that individuals with existing liver or kidney disease should approach the use of this combination medicine with caution. The body relies on these organs to process and clear the medication. Due to the potential for the medicine to accumulate, a healthcare professional may need to review the appropriateness or amount of the medicine prescribed.

Q: Does this medication cause dependence or withdrawal symptoms?

A: Official product information includes warnings that the combination of codeine and acetaminophen may be habit-forming, leading to the development of physical dependence. If the medication has been used for an extended period, medical supervision is recommended for discontinuation to manage potential withdrawal effects.

Q: Does Biragan Codein contain caffeine?

A: Some formulations of this combination medicine may include caffeine. Regulatory documents state that caffeine is sometimes added to enhance pain relief, particularly in certain headache treatments. If a formulation contains caffeine, patients are typically advised to limit their intake of additional caffeine-containing products.

How to Store and Dispose of Acetaminophen and Codeine Phosphate Tablets

Acetaminophen and Codeine Phosphate Tablets must be stored and handled according to specific regulatory requirements for controlled substances to prevent accidental exposure and misuse.

Storage Requirements

Condition	Requirement (Official Labeling)
Temperature	Store at Controlled Room Temperature (20 C to 25 C).
Environment	Protect from moisture and excessive heat. Do not store in the bathroom.
Security	Must be stored securely, out of the sight and reach of children, in a locked area or cabinet.
Container	Keep in the tightly closed container it was dispensed in.

Disposal Instructions

Disposal of unused or expired tablets must be done promptly.

Preferred Method: Utilize a medicine take-back program or a DEA-authorized collector site.

Alternative Method (if no take-back program is available): Render the tablets unusable by mixing them with an unpalatable substance (e.g., dirt or used coffee grounds). Place the mixture into a sealed bag and dispose of it in the household trash.